Company News
Kalaris Surge 29% on Phase 1a Results
Kalaris Therapeutics' stock rose 29% after reporting positive Phase 1a data for TH103 in neovascular AMD.
The expanded trial included 20 patients (17 treatment‑naive, 3 experienced) who completed six‑
